Overall sequencing results, obtained by both laboratories
| BRAF | KRAS | NRAS | PIK3CA | TP53 | |
| Mutation detected | 125 (9.7%) | 666 (51.6%) | 72 (5.6%) | 179 (13.9%) | 481 (37.3%) |
| Wildtype | 1135 (87.9%) | 598 (46.3%) | 1192 (92.3%) | 1066 (82.6%) | 229 (17.7%) |
| Failed samples | 28 (2.2%) | 24 (1.9%) | 25 (1.9%) | 43 (3.3%) | 19 (2.6%) |
| Not tested | 2 (0.2%) | 2 (0.2%) | 1 (0.1%) | 2 (0.2%) | 1 (0.1%) |
| Missing data | 1 (0.1%) | 1 (0.1%) | 1 (0.1%) | 1 (0.1%) | 561 (43.4%)* |
The breakdown of sequencing results by gene, and outcome for the 1291 tumour samples that were sequenced in either the Leeds or Cardiff laboratories between January 2014 and March 2020.
*As testing of TP53 mutation status only began in 2017, the 561 samples that had been sequenced prior to this date, were not eligible for TP53 mutation screening, hence the large amount of missing data indicated here.